Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Goes Fishing for Molecular Dx Future With Siemens

NEW YORK, Oct. 19 (GenomeWeb News) - Siemens, the giant German medical-systems manufacturer, will buy four Sequenom MassArray platforms as part of a broader collaboration to develop new molecular diagnostics platforms, Sequenom said today.

 

"We are interested in novel platforms for different nucleic acid based diagnostic applications," Mohammad Naraghi, senior vice president of business development at Siemens Medical Solutions, said in a statement. He said the MassArray technology "may be a good foundation" for the molecular diagnostics market.

 

As part of a "joint working group" the companies created for this collaboration, Siemens will install the four systems in certain diagnostics and clinical labs in Europeand North America, where Sequenom and Siemens will "execute a comprehensive functional requirement analysis," Sequenom said.

 

"There is a huge potential for innovation in diagnostics and IT systems," Erich Reinhardt, president and CEO of Siemens Medical Solutions, said in the statement. "Molecular medicine will have a significant impact on these platform developments."

 

Financial details of the collaboration were not disclosed.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.